Patricia Inácio, PhD,  science writer—

Healthcare costs continuously dropped for people with hereditary angioedema (HAE) who were on long-term preventive treatment with Takhzyro (lanadelumab), according to a retrospective analysis of healthcare insurance claims from a U.S. database. Findings were reported in a study, “Real-world changes in costs over time among…

Firazyr (icatibant injection) rapidly eased acute attack symptoms in two Japanese children with hereditary angioedema (HAE), according to a study led by Takeda Pharmaceuticals, its developer. The therapy’s safety and pharmacological profile was also consistent with previous observations of adults and other pediatric patients. Firazyr’s approval in…

An elderly woman developed angioedema about 20 days after being given ticagrelor, a medicine that prevents blood clots from forming and is commonly used to lower the risk of a heart attack or stroke. “Given the uncommon number of cases reported involving ticagrelor-induced angioedema and the even rarer, delayed…

Preventive treatment with Orladeyo (berotralstat) for up to two years led to prolonged periods of no swelling attacks in people with hereditary angioedema (HAE), irrespective of age, gender, or prior preventive treatments, according to a post-hoc analysis of the Phase 2/3 APeX-S trial. “These data demonstrate how our…

People with hereditary angioedema due to C1-inhibitor deficiency (C1-INH-HAE) typically experience a significantly delayed diagnosis — even with a family history positive for the disease, according to a nationwide study in Latvia. Indeed, the median delay in obtaining a diagnosis in the Northern European country is 20.5 years, researchers…

The prevalence of hereditary angioedema (HAE) in Asia-Pacific countries is lower than that reported for the disease in Western countries, according to data from an international survey. However, access to on-demand and preventive therapies to treat HAE is limited in these nations — a phenomenon researchers say is linked…

Researchers have reported the case of two men who were initially misdiagnosed with a rare type of hereditary angioedema (HAE) known as HAE-nC1INH-UNK when the correct diagnosis was the more common mast cell-mediated angioedema. This “exceedingly rare subtype of HAE … appears to be often diagnosed in patients who…

Xolair (omalizumab), an approved therapy for allergic asthma and chronic spontaneous urticaria (CSU), shows promise for treating idiopathic angioedema, according to data from a small Phase 4 trial. In the study, treatment for roughly six months with Xolair as an add-on therapy lessened disease activity when compared to…

Atorvastatin, a cholesterol-lowering medication, has been linked to angioedema for the first time in a recent case report, highlighting the need for comprehensive evaluation of all medications taken by patients, regardless of their medical history. “Statins cannot be disregarded as the primary or contributing cause of angioedema,” researchers…

Garadacimab, an investigational preventive treatment for hereditary angioedema (HAE), reduced the number of attacks for up to six months in patients 12 and older, according to top-line data from a Phase 3 trial. According to CSL Behring, the therapy’s developer, the study, called VANGUARD (NCT04656418), not only…